# 510(k) SUMMARY

This summary of $5 1 0 ( \mathbf { k } )$ safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR $\ S 8 0 7 . 9 2$ .

The Assigned 510(k) Number is: __K103484_

Date: April 12, 2011

Submitted by:

Wallac Oy, subsidiary of PerkinElmer 940 Winter Street Waltham, MA 02451 USA

Contact Person: Primary:

Susan K. Hamann Tel: 781-663-5872 Fax: 781-663-5983

# Secondary:

Kay A. Taylor Tel: 317-418-1735 Fax: 317-536-3064

# Trade Name:

$\mathsf { G S P } ^ { \otimes }$ Neonatal Thyroxine $\mathrm { ( T _ { 4 } ) }$ kit (3302-001U)

# Common Name:

GSP Neonatal Thyroxine $\mathrm { ( T _ { 4 } ) }$ kit

# Regulation:

21 CFR 862.1700

Classification Name:

Total Thyroxine Test System

Product Code:

KLI

Predicate Device:

AutoDELFIA® Neonatal Thyroxine T4 510(k) Number (K943416)

# Device Description:

The GSP Neonatal T4 assay is a solid phase time-resolved fluoroimmunoassay based on the competitive reaction between europium-labeled T4 and sample T4 for a limited amount of binding sites on T4 specific monoclonal antibodies (derived from mice). The use of 8-anilino-1-naphthalenesulfonic acid (ANS) and salicylate in the T4 Assay Buffer facilitates the release of T4 from the binding proteins. Thus the assay measures the total amount of T4 in the test specimen. A second antibody, directed against mouse IgG, is coated to the solid phase, and binds the IgG-thyroxine complex, giving convenient separation of the antibodybound and free antigen.

DELFIA Inducer dissociates europium ions from the labeled antibody into solution where they form highly fluorescent chelates with components of DELFIA Inducer.

The fluorescence in each well is then measured. The fluorescence of each sample is inversely proportional to the concentration of T4 in the sample.

Intended Use:

The GSP Neonatal IRT kit is intended for the quantitative determination of human thyroxine (T4) in blood specimens dried on filter paper as an aid in screening newborns for congenital (neonatal) hypothyroidism using the $\mathrm { G S P ^ { \otimes } }$ instrument.

Substantial Equivalence:

The ${ \mathrm { G S P } } ^ { \mathfrak { B } }$ Neonatal Thyroxine $\mathrm { ( T _ { 4 } ) }$ kit is uantial euvalet y marketed AutoDELFIA® Neonatal Thyroxine T4 (K943416). There are the following similarities and differences between the two kits:

<table><tr><td rowspan=2 colspan=1>PredicateDevice</td><td rowspan=2 colspan=1>FEATURE</td><td rowspan=2 colspan=1>Similarities (AutoDELFIA T4)</td><td rowspan=2 colspan=1>Differences (GSP T4)</td></tr><tr></tr><tr><td rowspan=1 colspan=1>AutoDELFIANeonatal T4 Kit</td><td rowspan=1 colspan=1>Intended User</td><td rowspan=1 colspan=1>Adequately trained laboratory personnel inlaboratories performing newborn screening.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>AutoDELFIANeonatal T4 Kit</td><td rowspan=1 colspan=1>Intended use</td><td rowspan=1 colspan=1>This kit is intended for the quantitativedetermination of human thyroxine (T4) inblood specimens dried on filter paper as anaid in screening newborns for congential(neonatal) hypothyroidism using theAutoDELFIA automatic immunoassaysystem.</td><td rowspan=1 colspan=1>The kit is intended for the quantitativedetermination of human thyroxine (T4) in bloodspecimens dried on filter paper as an aid inscreening newborns for congenital (neonatal)hypothyroidism using the GSP instrument.</td></tr><tr><td rowspan=1 colspan=1>AutoDELFIANeonatal T4 Kit</td><td rowspan=1 colspan=1>ChemicalPrinciple</td><td rowspan=1 colspan=1>The Neonatal T4 assay is a solid phasetime-resolved fluoroimmunoassay based onthe competitive reaction between europium-labeled T4 and sample T4 for a limitedamount of binding sites on T4 specificmonoclonal antibodies (derived from mice).The use of 8-anilino-1-naphthalenesulfonicacid (ANS) and salicylate in the T4 AssayBuffer facilitates the release of T4 from thebinding proteins. Thus the assay measuresthe total amount of T4 in the test specimen.A second antibody, directed against mouseIgG, is coated to the solid phase, and bindsthe IgG-thyroxine complex, givingconvenient separation of the antibody-boundand free antigen.Europium ions are dissociated from thelabeled antibody into solution where theyform highly fluorescent chelates withcomponents of the dissociation solution.The fluorescence in each well is thenmeasured. The fluorescence of each sampleis inversely proportional to the concentrationof T4 in the sample</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>AutoDELFIANeonatal T4 Kit</td><td rowspan=1 colspan=1>DissociationSolution</td><td rowspan=1 colspan=1>Enhancement Solution.</td><td rowspan=1 colspan=1>DELFIA Inducer</td></tr><tr><td rowspan=1 colspan=1>AutoDELFIANeonatal T4 Kit</td><td rowspan=1 colspan=1>DetectionPrinciple</td><td rowspan=1 colspan=1>Time-resolved fluorescence</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>AutoDELFIANeonatal T4 Kit</td><td rowspan=1 colspan=1>Specimen</td><td rowspan=1 colspan=1>Dried blood on filter paper disks with adiameter of approximately 3.2 mm (1/8 inch)</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>AutoDELFIANeonatal T4 Kit</td><td rowspan=1 colspan=1>Antibodies</td><td rowspan=1 colspan=1>Primary mouse monoclonal antibody andsecondary rabbit polyclonal antibody</td><td rowspan=1 colspan=1>Same</td></tr></table>

<table><tr><td rowspan=1 colspan=1>(p di) a</td><td rowspan=1 colspan=1>Saee</td><td rowspan=1 colspan=1>sae</td><td rowspan=1 colspan=1>(e ueeen s edede</td><td rowspan=1 colspan=1>saee</td><td rowspan=1 colspan=1>Saee</td><td rowspan=1 colspan=1>saee</td><td rowspan=1 colspan=1>Ciele croe cee(o 0~) 17a 8 &#x27;s</td><td rowspan=1 colspan=1>(/o 2~ Aoqe 1⊥7 i! &#x27;st</td><td rowspan=1 colspan=1>saee</td><td rowspan=1 colspan=1>au se oo  oc-nuMaj1 cses</td><td rowspan=1 colspan=1>Saee</td><td rowspan=1 colspan=1>aa be b ono sixeCeJotos o oo dae.&#x27;eqh sie-sooce</td><td rowspan=1 colspan=1>Tomm &#x27;snoy 7 + u0</td><td rowspan=1 colspan=1>Pied pa o n coeq Sp/ 20 adl%0&#x27;11%99%r o 10Wnn ihtnnW ii</td></tr><tr><td rowspan=1 colspan=1>(t h eelll</td><td rowspan=1 colspan=1>Sojq t o s ds</td><td rowspan=1 colspan=1>n o ae buy e  poae cn%99</td><td rowspan=1 colspan=1>Piiee Bade Jas(06 ou neaen)</td><td rowspan=1 colspan=1>wes p/brwes 7p/res 1p/rws p/bruns p/r2o /r 0m024∞16ABCDEF</td><td rowspan=1 colspan=1>T t o se os</td><td rowspan=1 colspan=1>c /  cs / mcs /r 1 cmAan xodd</td><td rowspan=1 colspan=1>:(w 1~)n3-1 mdok sig</td><td rowspan=1 colspan=1>o  o o Aoe pafl se</td><td rowspan=1 colspan=1>Jasg essb3eal oy</td><td rowspan=1 colspan=1>aun su   o-nuPoj 2 : (qoss</td><td rowspan=1 colspan=1>Co is aeue e peu</td><td rowspan=1 colspan=1> se  s  pioe aie ene bin</td><td rowspan=1 colspan=1>1m &#x27;snoy  + uu</td><td rowspan=1 colspan=1>Pid ye o aann pepuen c / 1  % 6  oeen esse-u% 0a ae ess-a1 0 ae 1o</td></tr><tr><td rowspan=1 colspan=1>EEERE</td><td rowspan=1 colspan=1>cafaos</td><td rowspan=1 colspan=1>sorce</td><td rowspan=1 colspan=1>Wwl</td><td rowspan=1 colspan=1>coontenuuncaieio</td><td rowspan=1 colspan=1>coouos</td><td rowspan=1 colspan=1>coontenuuconuo</td><td rowspan=1 colspan=1>teeer</td><td rowspan=1 colspan=1>Apoq</td><td rowspan=1 colspan=1>Jeg Besse</td><td rowspan=1 colspan=1>Pefels</td><td rowspan=1 colspan=1>Gao</td><td rowspan=1 colspan=1>catenoon</td><td rowspan=1 colspan=1>i Gonai</td><td rowspan=1 colspan=1>(i/c)Pasd</td></tr><tr><td rowspan=1 colspan=1>PrepedGae</td><td rowspan=1 colspan=1>NeTTrtaiACVA</td><td rowspan=1 colspan=1>NMTTaaAA</td><td rowspan=1 colspan=1>NeTeaAUCA</td><td rowspan=1 colspan=1>Ne t TejeaaiAUV</td><td rowspan=1 colspan=1>NMTTaAUUVA</td><td rowspan=1 colspan=1>NeT TaiAUV</td><td rowspan=1 colspan=1>Ne TreaiAUCEV</td><td rowspan=1 colspan=1>Ne t TjeaiAUA</td><td rowspan=1 colspan=1>NeTToaACVA</td><td rowspan=1 colspan=1>NT TtatAUVA</td><td rowspan=1 colspan=1>NeT TeatAUCA</td><td rowspan=1 colspan=1>Ne T TjealAUCCA</td><td rowspan=1 colspan=1>NeTTrjaAUCA</td><td rowspan=1 colspan=1>Ne TeeriAUVA</td></tr></table>

<table><tr><td rowspan=1 colspan=1>PredicateDevice</td><td rowspan=1 colspan=1>FEATURE</td><td rowspan=1 colspan=1>Similarities (AutoDELFIA T4)</td><td rowspan=1 colspan=1>Differences (GSP T4)</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Control 2; 8.08 μg/dL serumIntra-assay variation 10.6 %Inter-assay variation 7.1 %Total variation 12.7 %Control 3; 18.2 μg/dL serumIntra-assay variation 8.2%Inter-assay variation 4.3%Total variation 9.3 %</td><td rowspan=1 colspan=1>Sample 2; 4.8 μg/dLWithin run   7.3%Within lot    10.7%Total variation 11.4%Sample 3; 7.5 μg/dLWithin run    65%Within lot    8.4%Total variation 8.6%Sample 4; 16.6 μg/dLWithin run   4.5%Within lot    7.8%Total variation 8.5%Sample 5; 19.8 μg/dLWithin run    7.2%Within lot     9.9%Total variation 10.3%Sample 6; 21.4 μg/dLWithin run    7.%Within lot     9.8%Total variation 10.1%</td></tr><tr><td rowspan=1 colspan=1>AutoDELFIANeonatal T4 Kit</td><td rowspan=1 colspan=1>MeasuringRange</td><td rowspan=1 colspan=1>1.5 μg/dL to the highest level calibrator</td><td rowspan=1 colspan=1>1.6 to 30 µg/dL serum</td></tr><tr><td rowspan=1 colspan=1>AutoDELFIANeonatal T4 Kit</td><td rowspan=1 colspan=1>Limit of Blank</td><td rowspan=1 colspan=1>&lt; 1.5 μg/dL</td><td rowspan=1 colspan=1>0.457 μg/dL</td></tr><tr><td rowspan=1 colspan=1>AutoDELFIANeonatal T4 Kit</td><td rowspan=1 colspan=1>Limit of Detection</td><td rowspan=1 colspan=1>Not available</td><td rowspan=1 colspan=1>0.99 μg/dL</td></tr><tr><td rowspan=1 colspan=1>AutoDELFIANeonatal T4 Kit</td><td rowspan=1 colspan=1>Limit ofQuantitation</td><td rowspan=1 colspan=1>Not available</td><td rowspan=1 colspan=1>1.61 μg/dL</td></tr><tr><td rowspan=1 colspan=1>AutoDELFIANeonatal T4 Kit</td><td rowspan=1 colspan=1>Interference</td><td rowspan=1 colspan=1>Bilirubin at 20 mg/dL in has no significanteffect on the assay.</td><td rowspan=1 colspan=1>Icteric (unconjugated bilirubin ≤ 342 μmol/L,equivalent to 20 mg/dL in serum, and conjugatedbilirubin ≤ 237 μmol/L, equivalent to 20 mg/dLin serum) samples do not interfere with the assay.Lipemic samples (Intralipid&#x27; ≤ 15 mg/mL inserum) do not interfere with the assay. Added</td></tr></table>

<table><tr><td rowspan=1 colspan=1>PredicateDevice</td><td rowspan=1 colspan=1>FEATURE</td><td rowspan=1 colspan=4>Similarities (AutoDELFIA T4)</td><td rowspan=1 colspan=4>Differences (GSP T4)</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4></td><td rowspan=1 colspan=4>hemoglobin up to 15 g/L does not interfere withthe assay.</td></tr><tr><td rowspan=27 colspan=1>AutoDELFIANeonatal T4 Kit</td><td rowspan=27 colspan=2>Cross reactivity</td><td rowspan=2 colspan=1>Substance</td><td rowspan=2 colspan=2>Cross reactivity%</td><td rowspan=3 colspan=2></td><td></td><td rowspan=1 colspan=1>EY</td></tr><tr><td rowspan=2 colspan=1>Substance</td><td rowspan=2 colspan=1>Cross reactivity(%)</td></tr><tr><td rowspan=1 colspan=1>L-Thyroxine</td><td rowspan=1 colspan=2>100</td><td rowspan=1 colspan=2></td></tr><tr><td rowspan=5 colspan=1>3,3&#x27;5-Triiodo-L-thyronine (LT3)</td><td rowspan=5 colspan=2>0.89</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td rowspan=1 colspan=1>b</td><td></td><td></td></tr><tr><td rowspan=3 colspan=2></td><td></td><td></td><td></td></tr><tr><td></td><td rowspan=1 colspan=1>L-thyroxine</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=2 colspan=2></td><td rowspan=2 colspan=1>3,3&#x27;,5-Triiodo-L-thyronine (LT3)</td><td rowspan=2 colspan=1>1.67</td></tr><tr><td rowspan=2 colspan=1>3,3&#x27;,5-Triiodoaceticacid</td><td rowspan=2 colspan=2>0.45</td><td rowspan=2 colspan=2></td></tr><tr><td rowspan=2 colspan=2></td><td rowspan=2 colspan=1>3,3&#x27;,5-Triiodothyroaceticacid</td><td rowspan=2 colspan=1>0.14</td></tr><tr><td rowspan=1 colspan=1>3,5-Diiodo-L-thyronine</td><td rowspan=1 colspan=2>&lt;0.1</td><td rowspan=1 colspan=2></td></tr><tr><td rowspan=4 colspan=1>3,5-Diiodotyrosine(DIT)</td><td rowspan=4 colspan=2>&lt; 0.1</td><td rowspan=4 colspan=2></td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>b</td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>3,5-Diiodo-L-thyronine</td><td rowspan=1 colspan=1>&lt; 0.1</td></tr><tr><td rowspan=2 colspan=2></td><td rowspan=2 colspan=1>3,5-Diiodotyrosine (DIT)dihydrate</td><td rowspan=2 colspan=1>&lt; 0.1</td></tr><tr><td rowspan=1 colspan=1>5,5 Diphenylhydantoin</td><td rowspan=1 colspan=2>&lt; 0.1</td><td rowspan=1 colspan=2></td></tr><tr><td rowspan=1 colspan=1>3-iodo-L-tyrosine (MIT)</td><td rowspan=1 colspan=2>&lt;0.1</td><td rowspan=1 colspan=1></td><td></td><td rowspan=1 colspan=1>5,5-DiphenyIhydantoin</td><td rowspan=1 colspan=1>&lt;0.1</td></tr><tr><td rowspan=1 colspan=1>Phenylbutazone</td><td rowspan=1 colspan=2>&lt; 0.1</td><td></td><td></td><td rowspan=1 colspan=1>3-iodo-L-tyrosine (MIT)</td><td rowspan=1 colspan=1>&lt;0.1</td></tr><tr><td rowspan=2 colspan=1>6-n-Propyl-2-thiouracil</td><td rowspan=2 colspan=2>&lt; 0.1</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td rowspan=1 colspan=1>Phenylbutazone</td><td rowspan=1 colspan=1>&lt; 0.1</td></tr><tr><td rowspan=1 colspan=1>Methimazole</td><td rowspan=1 colspan=2>&lt; 0.1</td><td></td><td></td><td rowspan=1 colspan=1>6-n-Propyl-2-thiouracil</td><td rowspan=1 colspan=1>&lt; 0.1</td></tr><tr><td rowspan=1 colspan=1>L-Tyrosine</td><td rowspan=1 colspan=2>&lt;0.1</td><td></td><td rowspan=1 colspan=1>−</td><td rowspan=1 colspan=1>Methimazole</td><td rowspan=1 colspan=1>&lt; 0.1</td></tr><tr><td rowspan=2 colspan=1>Acetylsalicylic acid</td><td rowspan=2 colspan=1>&lt; 0.1</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>L-Tyrosine</td><td rowspan=1 colspan=1>&lt; 0.1</td></tr><tr><td rowspan=3 colspan=4></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=2 colspan=3>Acetylsalicylic acid</td><td rowspan=1 colspan=1>Acetylsalicylic acid</td><td rowspan=1 colspan=1>&lt; 0.01</td></tr><tr><td rowspan=1 colspan=1></td></tr></table>

Wallac Oy   
c/o Susan K. Hamann   
Regulatory Affairs Manager   
940 Winter Street   
Waltham, MA, 02451

Re: k103484 Trade Name: GSP Neonatal Thyroxine (T4) kit Regulation Number: 21 CFR $\ S 8 6 2 . 1 7 0 0$ Regulation Name: Total thyroxine test system. Regulatory Class: Class II Product Code: KLI Dated: November 24, 2010 Received: February 24, 2011

Dear Ms. Hamann:

We have reviewed your Section $5 1 0 ( \mathrm { k } )$ premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2 -

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796- 5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Gc.

Coulthey Harper, Ph.D.   
Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

# Indications for Use Form

510(k) Number (if known): _K103484

Device Name: The GSP Neonatal Thyroxine (T4) kit (3302-001U)

Indications for Use:

The GSP Neonatal Thyroxine (T4) kit is intended for the quantitative determination of human thyroxine (T4) in blood specimens dried on filter paper as an aid in screening newborns for congenital (neonatal) hypothyroidism using the GSP instrument.

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

Caroll Beren Office of In Vitro Diagnostic Device Evaluation and Safety 510k) K103484